Asia Deal Watch: HanAll, Daewoong Team With US Biotech In Parkinson's
Sino acquires Gmax's obesity drug candidate. Simcere partners with Mass General Brigham on select research projects.
You may also be interested in...
AstraZeneca is reportedly considering joining a prominent investment fund to spin off and list its Chinese entities, in an apparent bid to better insulate them against potential geopolitical risks.
Samsung Biologics has struck a deal worth over $400m to manufacture multiple biosimilars for Pfizer.
Indoco says it has marked a major milestone with a $4m deal to take a controlling stake in US firm Florida Pharmaceutical Products, strengthening the Indian company’s position in the US market.